Vivani Medical publishes investor presentation on NanoPortal long-acting GLP-1 implant pipeline for obesity

Vivani Medical Inc.

Vivani Medical Inc.

VANI

0.00
  • Vivani outlined its NanoPortal miniature drug-implant platform targeting ultra long-acting GLP-1 dosing, including once- or twice-yearly administration.
  • Lead candidate NPM-139 is a subdermal semaglutide implant for chronic weight management, with clinical program initiation targeted for mid-2026.
  • New agreement signed with Novo Nordisk to evaluate NPM-139; no exclusivity provisions tied to NPM-139 or the NanoPortal technology.
  • LIBERATE-1 first-in-human study met primary objectives on safety, tolerability, device performance, pharmacokinetics; no serious adverse events reported.
  • Presentation cited 2025 global GLP-1 sales above $79 billion; Morgan Stanley estimate put the global GLP-1 market at about $190 billion by 2035.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.